Abstract: Neuroprotective compounds for treating optic neuropathies and screening methods for identifying neuroprotective compounds.

Abstract: A system transfers energy wirelessly from a source to a sink as an EM near-field according to parameters. The source includes a receive RF chain, and a receive controller. The sink includes a transmit RF chain, and a receive controller. The receive controller measures the energy received as feedback information, which is transmitted to the sink. Then, the transmit controller dynamically varies the parameters to optimized the energy received at the sink.

Abstract: A system transfers energy wirelessly from a source to a sink as an EM near-field according to parameters. The source includes a receive RF chain, and a receive controller. The sink includes a transmit RF chain, and a receive controller. The receive controller measures the energy received as feedback information, which is transmitted to the sink. Then, the transmit controller dynamically varies the parameters to optimized the energy received at the sink.

Abstract: Neuroprotective compounds for treating optic neuropathies and screening methods for identifying neuroprotective compounds.

Abstract: This invention is directed to novel species-specific P. vivax malarial peptide antigens which are proteins or fragments of proteins secreted into the plasma of a susceptible mammalian host after infection, and to monoclonal or polyclonal antibodies directed against those antigens. The peptide antigens, monoclonal antibodies, and/or polyclonal antibodies are utilized in assays used to diagnose malaria, as well as to determine whether Plasmodium vivax is the species responsible for the infection.

Abstract: The present invention provides a recombinant protein comprising a 19 kDa C-terminal fragment of the surface protein 1 of the merozoite form of a Plasmodium type parasite other than Plasmodium vivax which is infectious in man.

Abstract: The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.

Abstract: This invention relates uses of components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on the components and their inhibitors.